Clinical trials: Guillain Barré Syndrome
Guillain-Barré Syndrome (GBS)
A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome
The main purpose of this study is to learn whether empasiprubart, when given in addition to intravenous immunoglobulin (IVIg), helps adults with Guillain-Barré syndrome (GBS) recover and whether it is safe.
- Trial name
- embridge (NCT07821762)
- Testing
- Empasiprubart IV, Intravenous immunoglobulin (IVIg)
- Volunteers
- 63 people
- Sponsor
- argenx
Guillain-Barré Syndrome
A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
This study is a multi center, open-label, study of ANX005 in combination with IVIg in subjects diagnosed with GBS.
- Trial name
- NCT04035135
- Testing
- ANX005, Intravenous immunoglobulin
- Where
- 2 sites in Bangladesh, Denmark
- Volunteers
- 14 people
- Sponsor
- Annexon, Inc.
Guillain-Barré Syndrome (GBS)
A Study of Imlifidase in Patients With Guillain-Barré Syndrome
The study participants are patients which have been diagnosed with Guillain-Barré Syndrome (GBS) and are planned to receive treatment with intravenous immunoglobulin (IVIg). IVIg is a standard of care treatment for GBS patients.
- Trial name
- NCT03943589
- Testing
- Imlifidase
- Where
- 11 sites in France, Netherlands and 1 more
- Volunteers
- 30 people
- Sponsor
- Hansa Biopharma AB
Spinal Cord Injury, Tetraplegia/Tetraparesis
Evaluation of Usability and Safety of the System Atalante in Patients With High Paraplegia and Tetraplegia
The objective of this clinical trial is to determine whether the Atalante X exoskeleton can be safely utilized by patients with tetraplegia and high paraplegia (at or above T4).
- Conditions
- Spinal Cord Injury, Tetraplegia/Tetraparesis, Paraplegia, Complete, Paraplegia, Incomplete
- Trial name
- QUATRO (NCT06939634)
- Testing
- Hands-free exoskeleton
- Where
- 3 sites in France
- Volunteers
- 35 people
- Sponsor
- Wandercraft
Guillain-Barré Syndrome
A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)
The goal of this research study is to determine whether it is safe and practical to give CK0801 (a cord-blood derived T-regulatory cell product) to patients with Guillain-Barré Syndrome (GBS).
- Trial name
- NCT03773328
- Testing
- CK0801
- Sponsor
- Cellenkos, Inc.
Guillain-Barré Syndrome
Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome
This study will carry out to assess the efficacy of GB-0998 (intravenous immunoglobulin;400mg/kg/day for five days) in the treatment of the Guillain-Barré Syndrome based on the changes in Hughes Functional Grade (FG) as primary…
- Trial name
- NCT02342184
- Testing
- GB-0998
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Japan Blood Products Organization
Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome
RWE-based Treatment Patterns and Outcomes in CIDP
To describe the demographics, clinical characteristics, treatment patterns and clinical outcomes of chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), and heredofamilial amyloidosis (hATTR)…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Hereditary Amyloidosis
- Trial name
- NCT05940922
- Testing
- No intervention. Retrospective observation only.
- Where
- United Kingdom
- Volunteers
- 170 people
- Sponsor
- RwHealth
COVID-19, Vaccine Adverse Reaction
National Vaccine Adverse Event Reporting Survey and Etiology
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use
- Trial name
- NVAERS (NCT05095844)
- Testing
- vaccinated
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- Neuroganics LLC
Guillain-Barre Syndrome
A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
This is a Phase 3, prospective, multicenter, placebo controlled, double blind, randomized study to investigate the efficacy and safety of eculizumab in participants with severe GBS, defined using the Hughes Functional Grade (FG)…
- Trial name
- NCT04752566
- Testing
- Eculizumab
- Where
- 22 sites in Japan
- Volunteers
- 57 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Guillain-Barré Syndrome
Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome
Patients diagnosed with Guillain-Barré syndrome were confirmed based on the diagnostic criteria for Guillain-Barré syndrome. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive…
- Trial name
- NCT02221271
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Guillain-Barré Syndrome
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab compared with placebo as an add-on therapy to intravenous immunoglobulin (IVIg) in participants with severe GBS.
- Trial name
- NCT05494619
- Testing
- Crovalimab, Intravenous immunoglobulin therapy
- Sponsor
- Hoffmann-La Roche
Guillain-Barre Syndrome
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
This study is intended to evaluate the efficacy and safety of ANX005 administered by intravenous (IV) infusion to participants recently diagnosed with Guillain-Barré Syndrome (GBS).
- Trial name
- NCT04701164
- Testing
- ANX005
- Where
- 11 sites in Bangladesh, Philippines
- Volunteers
- 242 people
- Sponsor
- Annexon, Inc.
Guillain-Barre Syndrome
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
- Trial name
- NCT07020819
- Testing
- Tanruprubart
- Where
- 30 sites in United States, Denmark and 3 more
- Volunteers
- 30 people
- Sponsor
- Annexon, Inc.